Diuretics: Understanding Their Mechanisms, Indications, and Adverse Effects

Diuretics aim to eliminate sodium, chloride, and water from the body via urine by targeting specific parts of the nephron. The video briefly reviews the anatomy of the nephron, including the Bowman's capsule, proximal convoluted tubule (PCT), loop of Henle (descending and ascending limbs), and distal convoluted tubule (DCT). Different sections reabsorb varying percentages of sodium and water (65% in PCT, 25% in ascending limb, 5% in early DCT, and 5% in late DCT). Diuretics work at these specific sites to inhibit reabsorption. Osmotic diuretics (Mannitol) act at the PCT and descending limb to pull water, causing massive water loss without significant sodium loss.

CAIs like acetazolamide work in the PCT. They inhibit the carbonic anhydrase enzyme, which is crucial for bicarbonate reabsorption. By inhibiting this enzyme, bicarbonate stays in the tubular lumen and is excreted, leading to a massive loss of bicarbonate in the urine, moderate sodium loss, and mild water loss. This can cause metabolic acidosis (non-anion gap).

Loop diuretics act on the ascending limb of the loop of Henle. They inhibit the sodium-potassium-2-chloride co-transporter, preventing the reabsorption of sodium, potassium, and chloride. This leads to massive loss of these ions and water in the urine. Additionally, by reducing potassium reabsorption and increasing positive charge in the tubular lumen, loop diuretics also cause the excretion of calcium and magnesium. These are powerful diuretics used for significant fluid removal.

Thiazide diuretics work in the early DCT by blocking the sodium-chloride co-transporter. This results in the loss of sodium, chloride, and water in the urine. A unique feature of thiazides is their ability to increase calcium reabsorption. By lowering intracellular sodium, they enhance the sodium-calcium exchanger, leading to less calcium excretion in the urine.

Potassium-sparing diuretics operate in the late DCT and collecting duct. There are two main types: aldosterone antagonists (spironolactone, eplerenone) and ENaC blockers (amiloride, triamterene). Aldosterone antagonists block aldosterone receptors, preventing the synthesis of ENaC channels and sodium-potassium ATPase, leading to retained potassium and mild sodium/water loss. ENaC blockers directly inhibit ENaC channels, achieving similar effects of potassium sparing and mild diuretic action.

Osmotic diuretics like Mannitol primarily increase blood osmolarity, drawing water from extravascular spaces (brain, vitreous humor) into the bloodstream. This is useful for reducing intracranial pressure (cerebral edema) and intraocular pressure (acute glaucoma). If kidneys function well, this leads to massive water diuresis, causing hypovolemia and hypernatremia. If kidneys are impaired, the excess fluid remains in the vasculature, potentially leading to pulmonary edema and hyponatremia.

Acetazolamide, a key CAI, induces metabolic acidosis by increasing bicarbonate excretion. This effect stimulates respiration, improving oxygenation and blowing off CO2, making it useful for altitude sickness and high-altitude pulmonary edema. It can also reduce aqueous humor production (glaucoma) and CSF production (idiopathic intracranial hypertension).

Loop diuretics (furosemide, torsemide, bumetanide, ethacrynic acid) are highly effective for rapid fluid removal. They exhibit a threshold dose for diuretic effect and a ceiling dose beyond which increased dosage offers no further benefit. Potency varies: bumetanide > torsemide > furosemide. Bioavailability differs, with furosemide having lower oral bioavailability. Beyond diuresis, loop diuretics are used to treat hyperkalemia and hypercalcemia due to their effects on potassium and calcium excretion.

Thiazide diuretics (hydrochlorothiazide, chlorothiazide, metolazone, chlorthalidone) are effective for hypertension due to vasodilation and reduced blood volume. Their ability to increase calcium reabsorption makes them beneficial for preventing kidney stones (calciuria) and potentially aiding in osteoporosis by increasing calcium availability for bone deposition.

Aldosterone antagonists (spironolactone, eplerenone) are crucial in conditions with excessive aldosterone, such as Conn's syndrome, and are used in hypertension patients with heart failure and hypokalemia due to their potassium-sparing and mortality-reducing effects. ENaC blockers (amiloride, triamterene) can treat nephrogenic diabetes insipidus, a condition where ADH is present but kidney tubules are unresponsive.

For patients with significant fluid overload (heart failure, CKD/AKI, iatrogenic fluid overload), a systematic approach is necessary. Start with a loop diuretic for maximal fluid removal. If hypernatremia develops or additional diuresis is needed, add a thiazide diuretic. To counteract metabolic alkalosis (caused by loops and thiazides) and enhance diuresis, a CAI can be added. Finally, to prevent hypokalemia and provide additional diuretic effect, a potassium-sparing diuretic completes the regimen. This combination maximizes efficacy while managing adverse effects.

In patients with cirrhosis and ascites, the underlying pathophysiology involves increased portal blood pressure, leading to systemic vasodilation and activation of the RAAS system, which causes sodium and water retention. The primary treatment involves aldosterone blockers (spironolactone) to counteract this effect, often combined with low-dose loop diuretics for enhanced fluid excretion. This approach helps reduce ascites and peripheral edema, distinguishing it from general fluid overload management.

A detailed discussion of adverse effects for each diuretic class: Loop diuretics can cause hypernatremia, hypovolemia, hypocalcemia, hypomagnesemia, hypokalemia, metabolic alkalosis, hyperuricemia, hyperglycemia, and ototoxicity. Thiazide diuretics are associated with hyponatremia, hypercalcemia, hypomagnesemia, hypokalemia, metabolic alkalosis, hyperuricemia, and hyperglycemia, plus hyperlipidemia. Potassium-sparing diuretics cause hyperkalemia and metabolic acidosis; aldosterone blockers can also lead to gynecomastia. CAIs induce metabolic acidosis, increase the risk of kidney stones, and may cause hyperammonemia and hypokalemia.

The video concludes with a series of clinical case studies demonstrating the application of diuretic knowledge. Cases include acute pulmonary edema management, altitude sickness prevention, ascites treatment in cirrhosis, kidney stone prevention, drug-induced gout, contraindications in hyperkalemia, metabolic alkalosis treatment, gynecomastia as a side effect, and combination therapy in heart failure with reduced ejection fraction, and resistant hypertension, solidifying the understanding of appropriate diuretic selection.